Health Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and… James Pereira Nov 21, 2022 OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will… Read More...
Health Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic… James Pereira Jun 22, 2022 VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with… Read More...
Health Vaccitech to Present at the H.C. Wainwright Global Investment Conference James Pereira May 20, 2022 OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage… Read More...
Health Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B… James Pereira Jan 14, 2022 OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”), a clinical-stage… Read More...
Health Vaccitech, 만성 HBV에 대한 임상1b/2a상 시험에서 긍정적인 초기 효능성 분석 결과 도출 James Pereira Dec 8, 2021 만성B형간염(CHB) 환자를 대상으로 한 3개월 간의 HBV002 임상연구 마친 27명의 환자들의 초기 데이터를 보면, 표면 항원(HBsAg) 수치가 눈에 띄는 변화를 나타냈으며, 이는 다른 종류의… Read More...
Health Vaccitech在慢性HBV的1b/2a期临床研究中报告了极具前景的中期疗效分析 James Pereira Dec 7, 2021 在慢性乙型肝炎(CHB)患者中,27名完成了3个月HBV002研究患者的中期数据表明,表面抗原(HBsAg)水平出现了显著变化,特别是在接受具有异源加强型(VTP-300)低剂量纳武单抗的人群中。 Stay connected… Read More...
Health Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference James Pereira Nov 25, 2021 OXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage… Read More...
Health 在中期分析中,Vaccitech的VTP-300对健康志愿者和慢性HBV感染患者中都具有良好耐受性,并可诱发T细胞对抗所有靶向HBV抗原 James Pereira Nov 13, 2021 HBV001和HBV002这两项研究的中期数据表明,在慢性乙型肝炎(CHB)患者中,ChAdOx1-HBV + MVA-HBV(VTP-300)的异源初免-加强载体组合诱发T细胞积极对抗靶向乙型肝炎病毒抗原。 Stay… Read More...
Health Vaccitech의 VTP-300, 건강한 지원자 및 만성B형간염 환자 모두가 보유한 모든 표적 HBV 항원에 대해 우수한 내약성 및 T세포 유도 능력 보였다는 초기 결과 발표 James Pereira Nov 13, 2021 HBV001 및 HBV002 연구의 초기 데이터, 만성B형간염(CHB) 환자의 경우 이종 프라임-부스트 벡터 조합인 ChAdOx1-HBV + MVA-HBV (VTP-300)가 B형간염 바이러스 항원 표적에 대해… Read More...
Health Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World… James Pereira Oct 13, 2021 OXFORD, United Kingdom, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage… Read More...